CN Patent

CN121668282A — 药物制剂

Assigned to Novo Nordisk AS · Expires 2026-03-17 · 0y expired

What this patent protects

本文公开了包含卡格列肽的水性药物制剂和包含司美格鲁肽的水性制剂。这两种药物制剂的组成允许它们在本文公开的双室医疗设备中呈现，以及使用本文公开的双室医疗设备施用。患有疾病如糖尿病和/或肥胖症和/或相关共病的个体可以受益于使用本文公开的医疗设备共同施用司美格鲁肽和卡格列肽以及/或者本文公开的两种液体药物制剂。

USPTO Abstract

本文公开了包含卡格列肽的水性药物制剂和包含司美格鲁肽的水性制剂。这两种药物制剂的组成允许它们在本文公开的双室医疗设备中呈现，以及使用本文公开的双室医疗设备施用。患有疾病如糖尿病和/或肥胖症和/或相关共病的个体可以受益于使用本文公开的医疗设备共同施用司美格鲁肽和卡格列肽以及/或者本文公开的两种液体药物制剂。

Drugs covered by this patent

Patent Metadata

Patent number
CN121668282A
Jurisdiction
CN
Classification
—
Expires
2026-03-17
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.